Mice Lacking Osteoblast ERFE Show Better Red Blood Cell Recovery Six Days After Bloodletting

Role of osteoblast-derived ERFE
Mice in which erythroferrone (ERFE) was selectively deleted from bone-forming osteoblasts showed better red blood cell recovery than controls six days after bloodletting. Recovery improved even though serum ERFE decreased and hepatic hepcidin gene expression increased. Published in PNAS, the study suggests that understanding ERFE function requires examining not only iron metabolism regulation but also interactions between osteoblasts and erythroid cells.
ERFE secreted by erythroblasts, red blood cell precursors, is known as an iron-regulatory factor that suppresses hepcidin. The supplied abstract explains that mice with systemic deletion of the Erfe gene have insufficient hepcidin suppression and reduced iron availability, delaying recovery after bloodletting. In prior work, the researchers found that osteoblasts also express ERFE. Here, they separately analyzed the role of osteoblast-derived ERFE when demand for red blood cell production rises.
Altered recovery and BMP4 response after selective deletion
The researchers crossed mice carrying a conditional Erfe allele with Col2.3-Cre mice to create an osteoblast-selective Erfe knockout model. When stress erythropoiesis was induced by bloodletting, serum ERFE decreased, while expression of the hepatic hepcidin gene Hamp increased. Yet red blood cell recovery on day six after bloodletting was better than in controls carrying the conditional Erfe allele. Bone marrow Erfe expression did not differ between the groups.
No differences were observed at baseline in red blood cell or reticulocyte counts, spleen size, or bone marrow cellularity. By contrast, expression of the erythropoietin (EPO) receptor gene Epor and the bone morphogenetic protein 4 (BMP4) gene Bmp4 increased in whole bone tissue in vivo and in osteoblasts analyzed ex vivo from the osteoblast-selective knockout model. Increased erythroid cell proliferation and improved responsiveness to EPO were also observed in a BMP4-dependent manner.
These findings provide evidence that the role of osteoblast-derived ERFE is difficult to explain solely by hepcidin suppression and increased iron supply. The researchers interpret the results as showing that loss of ERFE in osteoblasts improves red blood cell recovery under stress, and focus on mechanisms regulating interactions between osteoblasts and erythroblasts.
Distinguishing systemic from cell-specific functions
The delayed recovery known from systemic Erfe deletion and the improved recovery in this osteoblast-selective knockout point in opposite directions. However, the supplied abstract does not establish whether the two models were directly compared in this experiment. The findings should therefore be interpreted with the distinction between systemic ERFE deletion and deletion in a specific cell type in mind.
The results come from a mouse bloodletting model and osteoblast analyses. The available abstract does not report sample size, the amount of blood removed, the quantitative magnitude of improved recovery, or long-term follow-up results. Although a BMP4-dependent response was observed, it would also be premature to conclude that the full signaling pathway has been defined. The supplied material cannot establish the efficacy or safety of anemia treatment in humans. Follow-up studies should examine cell-specific ERFE functions alongside the relationship between iron metabolism and red blood cell production.
Source: Europe PMC abstract and bibliographic record, original paper DOI 10.1073/pnas.2537627123.
Proceedings of the National Academy of Sciences, Volume 123, Issue 18, May 2026. SignificanceBone marrow erythroferrone (ERFE) suppresses hepcidin via bone morphogenetic protein (BMP) sequestration, increasing iron availability during stress erythropoiesis. We previously showed that ERFE is produced by osteoblasts and controls bone ...
This study provides preclinical evidence that anemia-related targets should be assessed by considering not only the total amount of ERFE but also which cells produce it. In the osteoblast-selective knockout, increased hepatic Hamp expression occurred alongside improved red blood cell recovery. Changes in hepcidin gene expression alone may therefore not predict the direction of recovery. Follow-up preclinical studies could modulate the osteoblast ERFE pathway and measure BMP4-dependent EPO responses, red blood cell recovery, and changes in iron metabolism together. Whether the genetic knockout findings can be reproduced by pharmacological modulation, and whether they apply to other anemia models or humans, requires separate validation. The current evidence does not establish treatment efficacy for refractory anemia or a treatment strategy for any specific patient group.